Gynaecology Flashcards
Urinary incontinence: Treatment
Stress: pelvic floor muscle training, 8 contractions performed 3 times per day for a minimum of 3 months, surgical
Urge: bladder retraining (lasts for a minimum of 6 weeks, antimuscarinics are first-line. oxybutynin (immediate release), tolterodine (immediate release) or darifenacin (once daily preparation). Avoid immediate release oxybutynin in ‘frail older women’
mirabegron (a beta-3 agonist) may be useful if there is concern about anticholinergic side-effects in frail elderly patients
Urinary incontinence: Classification
Overactive bladder (OAB)/urge incontinence: due to detrusor overactivity
Stress incontinence: leaking small amounts when coughing or laughing
Mixed incontinence: both urge and stress
Overflow incontinence: due to bladder outlet obstruction, e.g. due to prostate enlargement
Urinary incontinence: Risk factors
advancing age previous pregnancy and childbirth high body mass index hysterectomy family history
Premenstrual syndrome: Treatment
NSAIDs, COC, CBT, SSRIs
Cervical cancer screening: Age
25-49 years: 3-yearly screening
50-64 years: 5-yearly screening
cervical screening cannot be offered to women over 64 (unlike breast screening, where patients can self refer once past screening age)
Cervical cancer screening: Special situations
cervical screening in pregnancy is usually delayed until 3 months post-partum unless missed screening or previous abnormal smears.
women who have never been sexually active have very low risk of developing cervical cancer, therefore, they may wish to opt-out of screening
Cervical cancer screening: Aim
to detect pre-malignant changes rather than to detect cancer
Cervical cancer screening: Weakness
cervical adenocarcinomas, which account for around 15% of cases, are frequently undetected by screening
Cervical cancer screening: Methods
Usually done at mid-cycle
Liquid-based cytology advantages:
reduced rate of inadequate smears
increased sensitivity and specificity
Endometrial hyperplasia: Risk factors
Taking oestrogen unopposed by progesterone Obesity Late menopause Early menarche Aged over 35-years-old Being a current smoker Nulliparity Tamoxifen
Tamoxifen is a risk factor due to its pro-oestrogen effect on the uterus and bones. It does also have an anti-oestrogen effect on the breast.
Endometrial hyperplasia: Types
simple
complex
simple atypical
complex atypical
Endometrial hyperplasia: S/S
abnormal vaginal bleeding e.g. intermenstrual
Endometrial hyperplasia: Treatment
- simple endometrial hyperplasia without atypia: high dose progestogens with repeat sampling in 3-4 months. The levonorgestrel intra-uterine system may be used
- atypia: hysterectomy is usually advised
Hyperemesis gravidarum: Association
multiple pregnancies trophoblastic disease hyperthyroidism nulliparity obesity
Smoking is associated with a decreased incidence of hyperemesis.
Hyperemesis gravidarum: Traid
5% pre-pregnancy weight loss
dehydration
electrolyte imbalance
Hyperemesis gravidarum: Treatment
- 1st line - antihistamines (promethazine, cyclizine)
- ondansetron and metoclopramide
- metoclopramide may cause extrapyramidal side effects
- ginger and P6 (wrist) acupressure
- admission may be needed for IV hydration
Hyperemesis gravidarum: Complications
Wernicke's encephalopathy Mallory-Weiss tear central pontine myelinolysis acute tubular necrosis fetal: small for gestational age, pre-term birth
Cervical smear (Mild dyskaryosis): Management
Test for HPV
if HPV negative the patient goes back to routine recall
if HPV positive the patient is referred for colposcopy
Cervical smear (Moderate CIN IIor severe CIN IIIdyskaryosis): Management
urgent colposcopy within 2 weeks
Repeat 6 months after treatment for ‘test of cure’ repeat cytology in the community.
Cervical smear: High-risk subtypes of HPV
16, 18, 33
Cervical smear: Opting out
who have never been sexually active have very low risk of developing cervical cancer therefore they may wish to opt out of screening
Most common type of ovarian pathology associated with Meigs’ syndrome
Fibroma
Most common benign ovarian tumour in women under the age of 25 years
Dermoid cyst (teratoma)
Most common cause of ovarian enlargement in women of a reproductive age
Follicular cyst
Corpus luteum cyst: What is
during the menstrual cycle if pregnancy doesn’t occur the corpus luteum usually breaks down and disappears. If this doesn’t occur the corpus luteum may fill with blood or fluid and form a corpus luteal cyst
more likely to present with intraperitoneal bleeding than follicular cysts
Female genital mutilation: Types
Female Genital Mutation in under 18s - mandatory reporting duty to POLICE applies
Four types
Ovarian cyst: Types
Simple: unilocular, more likely to be physiological or benign
Complex: multilocular, more likely to be malignant
Ovarian cyst (Premenopausal): Management
-a conservative approach may be taken for younger women (especially if < 35 years) as malignancy is less common. If the cyst is small (e.g. < 5 cm) and reported as ‘simple’ then it is highly likely to be benign. A repeat ultrasound should be arranged for 8-12 weeks and referral considered if it persists
Ovarian cyst (Postmenopausal): Management
- by definition physiological cysts are unlikely
- any postmenopausal woman with an ovarian cyst regardless of nature or size should be referred to gynaecology for assessment
Cervical smear: “Inadequate”
Repeat in 3 months
3 consecutive “inadequate” needs colposcopy
Body temperature and ovulation
Body temperature rises following ovulation
Menstrual cycle phase
Menstruation 1-4
Follicular phase (proliferative phase) 5-13
Ovulation 14
Luteal phase (secretory phase) 15-28